Septodont's Novocol Pharma secures $26M

By staff writers

March 23, 2021 -- Septodont's Novocol Pharma division has secured $32.7 million Canadian ($26 million U.S.) from the Canadian government to further develop its injectable products.

The funding will increase biomanufacturing capability of fill-finish sterile injectables at Novocol Pharma's facility in Cambridge, Ontario, Septodont said.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking